Article Sidebar

Submitted
Apr 21, 2021
Published
Apr 21, 2021
Download
PDF
Statistic
Read Counter : 1179 Download : 90

Main Article Content

Abstract

Introduction
Diabetes mellitus (DM) is a leading cause of mortality and an increasing health burden with a prevalence of 8.3% globally and 9.1% in India (IDF). Prevention of complications and improving quality of life are the principle goals in its management. DPP-4 inhibitors have a potential vasoprotective effect mediated by stromal cell derived factor-1a. Teneligliptin a novel, highly selective, more potent agent compared to Sitagliptin provides sustained glycaemic control, decreases cardiovascular complications, has additional beneficial pleiotropic metabolic effects and also safe in renal impairment.


Objective


To evaluate the glycaemic and non-glycaemic effects of TeneligliptinvsSitagliptin as add on therapy to metformin.


Materials and methods


After obtaining Institutional Ethics Committee approval and written informed consent, 60 subjects with T2DM who failed to achieve glycaemic control with metformin (500mg TID) alone for 3 months were randomized in 1:1 ratio to receive Teneligliptin 20mg OD and Sitagliptin 100mg OD as add on therapy. Patients were followed up at 4, 8 and 12 weeks for glycaemic and non-glycaemic effects. Adverse drug reactions (ADRs), if any were recorded and graded according to severity.


Results


There was a statistically significant decrease in FBS (p<0.05, p<0.001) and PPBS (p<0.01, p<0.001) in patients treated with Teneligliptin on week 8 & week 12 from baseline compared to those treated with Sitagliptin. The reduction in HbA1c (p<0.0001), LDL-CH (p<0.0001) & TC (p<0.001) on week 12 from baseline was also significantly more in the Teneligliptin group.


Conclusion


Teneligliptin may be an effective and safe treatment option in reducing both glycaemic and non-glycaemic parameters as an add-on therapy in Type 2 DM with good patient tolerability.

Keywords

Teneligliptin Type 2 DM Sitagliptin DPP4 Inhibitors

Article Details

How to Cite
C. R. Jayanthi, Arjun Subash, & Raveendra K R. (2021). Comparison of efficacy and safety of teneligliptin versus sitagliptin as add on to metformin in type 2 diabetes mellitus at a tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 208-217. https://doi.org/10.61096/ijrpp.v6.iss2.2017.208-217
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Gupta M, Singh R, Lehl SS. Diabetes in India: a long way to go. Int J Sci Rep. 1(1), 2015, 1- 2.
  2. [2]. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). CardiovascDiabetol. 2012, 11:92
  3. [3]. International Diabetes Federation, World Diabetes Foundation. Diabetes atlas 2003. Brussels: International Diabetes Federation; 2003.
  4. [4]. Deshmukh V, Sathyanarayana S, Menon S, Patil S, Jones R, Uppal S, et al. Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study. Indian J EndocMetab. 19, 2015, 256- 61.
  5. [5]. Balas B, DeFronzo RA. The Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes. European endocrine disease 2, 2007, 45-50.
  6. [6]. Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today (Barc) 49(10), 2013, 615-29
  7. [7]. Maladkar M, Sankar S, Kamat K. Teneligliptin: Heralding Change in Type 2 Diabetes. Journal of Diabetes Mellitus. 6, 2016, 113-131.
  8. [8]. Raz I, Hanefeld M, Xu L, Caria C, Herman DW, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 49, 2016, 2564- 2571.
  9. [9]. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis.AdvTher. 29(1), 2012, 14-25.
  10. [10]. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 6, 2015, 386.
  11. [11]. Kalra S, Das AK, Sahay R. Managing Diabetes: The Drivers of Change. Journal of Social Health & Diabetes. 1, 2013, 3-5.
  12. [12]. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase -4 inhibitors and sulphonylureas. Diabetes Obesity and Metabolism. 18, 2015, 333-347.
  13. [13]. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 47(11), 1998, 1663-70.
  14. [14]. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S et al. A Comparative Study of the Binding Modes of Recently Launched Dipeptidyl Peptidase IV Inhibitors in the Active Site. Biochemical and Biophysical Research Communications. 434, 2013, 191-196.
  15. [15]. Kushwaha RN, Haq W, Katti SB. Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview. Chemistry & Biology Interface. 4, 2014, 137-162.
  16. [16]. Wilmot E, Idris I. Early onset type 2 diabetes: risk factors, clinical impact and management. TherAdv Chronic Dis. 5(6), 2014, 234–244.
  17. [17]. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev 37(3), 2016, 278-316.
  18. [18]. Ghosh S, Trivedi S, Sanyal D, Modi K, Kharb S. Teneligliptin real -world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 9, 2016, 347–353.
  19. [19]. Kadowaki T, Kondo K. Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes ObesMetab. 15(9), 2013, 810–818.
  20. [20]. Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC et al. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes ObesMetab. 18(5), 2016, 528-32.
  21. [21]. Eu JK, Kyong YJ, YoonJY, Kyoung MK, Jae HM, Sung HC et al. Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. Plos one. 10(6), 2015, e0129477.
  22. [22]. Eiji K, Mitsuru H, Yu I. Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes. J Clin Med Res. 6(4), 2014, 287-294.
  23. [23]. Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: A 4-week, randomized, double-blind, placebo-controlled trial. Diabetes ObesMetab. 14, 2012, 1040–6.
  24. [24]. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6, 2013, 187-195.
  25. [25]. Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y et al. DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes. Drug Research. 65, 2015, 532-534
  26. [26]. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Frontiers in Immunology. 6, 2015, 386.
  27. [27]. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. AdvTher. 29(1), 2012, 14-25.
  28. [28]. Zhong J, Gong Q, Goud A, SrinivasamaharajSvidya S, Rajagopalan S. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. 2015, 2015, 1-14.